David Oxlade joins TranScrip Partners
This article was originally published in Scrip
TranScrip Partners, a pharmaceutical development company formed in 2008 to provide advice and support to pharmaceutical and biotechnology companies, has appointed David Oxlade chairman of the board. In 2006, Mr Oxlade was appointed chairman of BioAnaLab, which was acquired by Millipore this year. He is the former CEO of Xenova, and, prior to their acquisition by Roche, he also spent 14 years working for Boehringer Mannheim and seven years serving as president of Syva.
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.